

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- The IMspire150 trial assessed the addition of which of the following anti-PD-1/PD-L1 antibodies to vemurafenib/cobimetinib for previously untreated advanced melanoma with a BRAF V600 mutation?

  - Atezolizumab
  - Pembrolizumab
  - Nivolumab
- Results from the Phase II IMMUNED study evaluating adjuvant nivolumab alone or in combination with ipilimumab for patients with fully resected or irradiated Stage IV melanoma with no evidence of disease after surgery demonstrated which recurrence-free survival outcome?

  - A significant improvement with nivolumab or nivolumab/ipilimumab compared to placebo
  - No significant improvement with either nivolumab or nivolumab/ipilimumab compared to placebo
- Patients with melanoma who receive vemurafenib/cobimetinib are more likely than those who receive dabrafenib/trametinib or encorafenib/binimetinib to experience which of the following side effects?

  - Fever
  - Fatigue
  - Photosensitivity
- The COMBI-AD study assessed which BRAF/MEK combination in the adjuvant setting for patients with Stage III melanoma with BRAF V600 mutations?

  - Encorafenib/binimetinib
  - Vemurafenib/cobimetinib
  - Dabrafenib/trametinib
- Results from the Phase III CheckMate 238 study comparing adjuvant nivolumab to ipilimumab for resected Stage IIIB, IIIC or IV melanoma demonstrated which of the following outcomes with respect to 48-month recurrence-free survival for all patients?

  - Significant improvement with adjuvant nivolumab
  - Significant improvement with adjuvant ipilimumab
  - Similar outcomes in both study arms
- Results of the Phase III COLUMBUS trial evaluating encorafenib/binimetinib versus vemurafenib or encorafenib for patients with advanced melanoma with a BRAF V600 mutation demonstrated an improvement in which endpoint with encorafenib/binimetinib compared to vemurafenib?

  - Overall survival only
  - Progression-free survival (PFS) only
  - Both overall and progression-free survival
- Which of the following drug types best describes the mechanism of action of the novel agent spartalizumab?

  - BRAF inhibitor
  - Anti-PD-1 antibody
  - Anti-PD-L1 antibody
- According to preliminary results from CheckMate 915, a randomized Phase III study evaluating nivolumab with ipilimumab versus nivolumab alone as adjuvant therapy after complete surgical removal of Stage IIIB, IIIC, IIID or IV melanoma, which statement is true regarding recurrence-free survival with the combination in the all-comer (intent-to-treat) population?

  - A statistically significant benefit was not reached
  - A statistically significant benefit was achieved

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

9. Final results from the Phase III KEYNOTE-054 trial evaluating pembrolizumab versus placebo after complete resection of high-risk Stage III melanoma demonstrated which of the following outcomes regarding distant metastasis-free survival with pembrolizumab?
- a. Improvement for patients with PD-L1-positive tumors
  - b. Improvement for patients with PD-L1-positive or PD-L1-negative tumors
10. Which of the following drug types best describes the mechanism of action of the novel agent bempegaldesleukin?
- a. CD-122-preferential interleukin-2 receptor agonist
  - b. Immune checkpoint inhibitor
  - c. MEK inhibitor